Two Sigma Advisers LP Invests $30,000 in 908 Devices Inc. (NASDAQ:MASS)

Two Sigma Advisers LP bought a new stake in shares of 908 Devices Inc. (NASDAQ:MASS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 13,500 shares of the company’s stock, valued at approximately $30,000.

Several other large investors have also recently made changes to their positions in the company. Prudential Financial Inc. purchased a new position in 908 Devices in the fourth quarter valued at $34,000. Occudo Quantitative Strategies LP acquired a new stake in shares of 908 Devices during the 4th quarter valued at about $36,000. Hsbc Holdings PLC increased its stake in shares of 908 Devices by 32.2% in the 4th quarter. Hsbc Holdings PLC now owns 21,007 shares of the company’s stock valued at $46,000 after purchasing an additional 5,112 shares in the last quarter. Stifel Financial Corp purchased a new position in shares of 908 Devices in the 4th quarter valued at about $52,000. Finally, Concurrent Investment Advisors LLC acquired a new position in 908 Devices in the 4th quarter worth about $52,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 908 Devices in a report on Saturday, May 24th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, 908 Devices currently has an average rating of “Moderate Buy” and an average price target of $5.33.

908 Devices Stock Performance

NASDAQ:MASS opened at $6.94 on Monday. The stock has a market capitalization of $248.88 million, a PE ratio of -3.92 and a beta of 0.29. 908 Devices Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $7.32. The company has a fifty day moving average of $5.03 and a two-hundred day moving average of $3.55.

908 Devices (NASDAQ:MASS) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.05. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%. The firm had revenue of $11.78 million during the quarter, compared to the consensus estimate of $11.90 million. Research analysts forecast that 908 Devices Inc. will post -1.99 earnings per share for the current year.

Insider Transactions at 908 Devices

In other 908 Devices news, CFO Joseph H. Iv Griffith sold 6,940 shares of the stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $7.08, for a total value of $49,135.20. Following the completion of the sale, the chief financial officer now owns 102,930 shares in the company, valued at approximately $728,744.40. This represents a 6.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark Spoto bought 10,000 shares of the stock in a transaction dated Wednesday, May 14th. The shares were bought at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the acquisition, the director now owns 62,971 shares in the company, valued at approximately $270,145.59. The trade was a 18.88% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 23.70% of the company’s stock.

908 Devices Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.